Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (OP:SKYE)

N/A UNCHANGED
Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Skye Bioscience, Inc. - Common Stock

< Previous 1 2 Next >
Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by more than 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Cannabis Stock Gainers And Losers From August 25, 2023
 
Via Benzinga
Topics Cannabis
Marijuana Stock Movers For August 23, 2023
 
Via Benzinga
Topics Cannabis
Cannabis Stock Gainers And Losers From August 24, 2023
 
Via Benzinga
Topics Cannabis
Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor
Skye Bioscience, Inc. (OTCQB: SKYE) has undertaken a strategic initiative that expands the company's resources and technologies focused on developing therapeutic products focused on the endocannabinoid... 
Via Benzinga
Marijuana Stock Movers For August 22, 2023
 
Via Benzinga
Topics Cannabis
Cannabis Stock Movers For August 18, 2023
 
Via Benzinga
Topics Cannabis
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
 
Via Benzinga
Topics Cannabis
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
 
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
 
Via Benzinga
Topics Cannabis
Cannabis Stock Movers For July 21, 2023
 
Via Benzinga
Cannabis Stock Gainers And Losers From August 16, 2023
 
Via Benzinga
Topics Cannabis
Skye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical Trial
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announced that its contract... 
Via Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
 
Via Benzinga
Topics Cannabis
Short Volatility Alert: Skye Bioscience
On Tuesday, shares of Skye Bioscience (OTC: SKYE) experienced volatile short activity. After the activity, the stock price went up +3.03% to $0.017. The overall sentiment for SKYE has been Bullish. 
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
 
Via Benzinga
Topics Cannabis
Ethics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. 
Via Benzinga
Marijuana Stock Movers For August 8, 2023
 
Via Benzinga
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Marijuana Stock Movers For August 2, 2023
 
Via Benzinga
SOL Global Reduces Principal Amount Of Credit Facility From $50M To $4.52M, Announces Management Changes
SOL Global Investments Corp. (OTCQB: SKYE) (CSE:SOL) (FSE:9SB) announced that it is up to date on all interest payments and has repaid an additional $1.0 million towards its $50 million credit facility... 
Via Benzinga
Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received a positive recommendation following a... 
Via Benzinga
Marijuana Stock Movers For August 1, 2023
 
Via Benzinga
Skye One Step Closer To Phase 2 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
Skye Bioscience, Inc. (OTCQB: SKYE) a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reported that its phase 2 clinical trial protocol has received... 
Via Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
Via Benzinga
Marijuana Stock Movers For July 31, 2023
 
Via Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
 
Via Benzinga
Cannabis Stock Gainers And Losers From July 26, 2023
 
Via Benzinga
Cannabis Stock Movers For July 24, 2023
 
Via Benzinga
Cannabis Stock Movers For July 20, 2023
 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.